The U.S. Food and Drug Administration (FDA) has cleared Oricell Therapeutics’ Investigational New Drug (IND) application for OriCAR-017 for patients with relapsed/refractory multiple myeloma (R/R MM).   OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D. The therapy leverages Oricell’s proprietary platforms including OriAb antibodies, OriCAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of re...